The arthritic Paradigm

Paradigm Biopharma (ASX: PAR) listed on the ASX in August 2015. The company focuses on repurposing pentosan polysulphate sodium (PPS) and CEO Paul Rennie tells Alan Kohler Paradigm has an exclusive deal with the only maker of pentosan for arthritic use.

To listen to the interview (or read the transcript), unlock this article for $1, and you gain access to the whole website for 1 month. Click here.

Every week you get:

  • 5 ASX listed investable companies and 3 tops stocks
  • Cryptocurrency podcast plus other investment podcasts and interviews
  • Alan’s Saturday Overview
  • Weekly Funds and Broker Research reports
  • Access to Private Facebook group with Live Q&A

Unlock this article (and more) for $1

Stay up to date and make better informed decisions.
Get access to all this exclusive content and so much more every week!

If you are a member, login here.